Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight
Sign up
now
|
|
|
Elsevier Business
Intelligence/Windhover
10 Hoyt Street
Norwalk, CT 06851
Tel: 203-838-4401
I-95 South:
Exit 16 (East Ave.). Take right at end. At 4th light, take left onto East Wall St. At 1st light, take right onto Main St. Take 2nd left onto Hoyt St. Windhover is second driveway on right. Door has blue awning.
|
I-95 North:
Exit 16 (East Ave.). Take left at end. At fifth light, take left onto East Wall St. At 1st light, take right onto Main St. Take 2nd left onto Hoyt St. Windhover is second driveway on right. Door has blue awning.
|
Merrit Parkway North:
Exit 39A (Route 7 Connector). Take Exit 1, and bear right at bottom of exit ramp. Make your first right onto Belden Ave. At the second traffic light make a left onto Cross St. Cross train tracks and make first right onto Hoyt Street. Windhover's visitor lot is located on your left hand side, across from McMahon Ford's lot. Door has blue awning.
|
Merrit Parkway South:
Exit 40A (Route 7 / Main Avenue). At bottom of exit ramp, take a right onto Route 7 South (Main Ave.). Continue on Rt. 7 South to Route 123 intersection (Dunkin Donuts landmark on right). Bear left onto Route 123 South (still considered Main Ave.). Continue to intersection of 123 South and Route 1. Continue straight one more block, Hoyt Street is on right after Family Diner. Windhover's visitor lot is second driveway on right, door has blue awning.
|
|
|
 |
|
 |
|
|
| |
 |
Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs. . . [MORE] (IN VIVO)
Bioactive Technologies For Bone Replacement
Expanded indications for bone morphogenetic proteins and new alternatives to those first-generation bone growth factors have the potential to grow the $2 billion market for bone replacement materials. . . [MORE] (Start-Up)
Laser Cataract Surgery Comes into Focus at ASCRS
The mood was primarily upbeat at April's annual meeting of the American Society of Cataract and Refractive Surgery. Most in attendance expected a modest rebound in procedure volumes for 2010. . . [MORE] (Medtech Insight)
FDA, Drug Development and Health Care Reform: A Panel Discussion
Current and former FDA officials and a former Big Pharma head of R&D discuss FDA and the relationship between a regulator and the industry it regulates when it comes to drug development. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|
